The same group showed similar results with increased PFS for patients with high miR-126 expression (p = 0.005) when assessing the clinical outcome of patients with metastatic colorectal cancer treated with chemotherapy combined with Bevacizumab (anti-VEGF-A)22. Here, VEGFA is linked to metastatic colorectal cancer.